INIA BIOSCIENCES, INC.

Boston, MA · Founded 2021 · CIK 0002038627 · Medtech

Ultrasound-based external medical device that stimulates splenic nerves to modulate immune response and reduce organ transplant rejection

iniabiosciences.com →
Grants
$275K
1 award
Sector median: 1
Raised
$200K
1 Form D · Sep 2024
24 months since last filing
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection$275,000
Private capital raisedForm D · SEC$200,000
Federal grant · SBIR/STTRForm D · SEC

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1179ANALYTICAL DIAGNOSTIC SOLUTIONS INC——
1180IMMUNO TECHNOLOGIES INC——
1181PERFUSIO CORP.—$11M
1182INIA BIOSCIENCES, INC.—$200K
1183INTRINSIC LIFESCIENCES, LLC——
1184CubeWorks, Inc.—$18M
1185NOVOTHELIUM, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 3 related persons
  • Michael HoganDirector · Executive Officer
  • Shen NingDirector · Executive Officer
  • Dragana SavicDirector · Executive Officer

Patents

USPTO · 0 granted of 3
  • Wearable Ultrasound Device And Harness For Immunomodulation, And Uses Thereofapplication
  • Wearable Ultrasound Device And Harness For Immunomodulation, And Uses Thereofapplication
  • Wearable Ultrasound Devices And Methods Of Useapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.